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Summary. The European Working Group on Clinical Cell
Analysis (EWGCCA) has, in preparation for a multicentre
peripheral blood stem cell clinical trial, developed a single-
platform ¯ow cytometric protocol for the enumeration of
CD34 stem cells. Using this protocol, stabilized blood and
targeted training, the EWGCCA have attempted to standard-
ize CD34 stem cell enumeration across 24 clinical sites.
Results were directly compared with participants in the UK
National External Quality Assessment Scheme (NEQAS)
for CD34 Stem Cell Quanti®cation that analysed the same
specimens using non-standardized methods. Two bead-
counting systems, Flow-Count and TruCount, were also
evaluated by the EWGCCA participants during trials 2 and
3. Using Flow-Count, the intralaboratory coef®cient of
variation (CV) was # 5% in 39% of the laboratories (trial
1), increasing to 65% by trial 3. Interlaboratory variation
was reduced from 23´3% (trial 1) to 10´8% in trial 3. In
trial 2, 70% of laboratories achieved an intralaboratory CV
# 5% using TruCount, increasing to 74% for trial 3; the
interlaboratory CV was reduced from 23´4% to 9´5%.
Comparative analysis of the EWGCCA and the UK NEQAS
cohorts revealed that EWGCCA laboratories, using the
standardized approach, had lower interlaboratory varia-
tion. Thus, the use of a common standardized protocol and
targeted training signi®cantly reduced intra- and inter-
laboratory CD34 cell count variation.
Keywords: CD34 stem cell enumeration, ¯ow cytometry,
standardized protocols, clinical cell analysis.
The use of speci®c treatment and mobilization regimes that
can signi®cantly increase the numbers of circulating CD34
stem cells in both patients and healthy donors is now the
preferred option for autografting (Henon, 1993). As a result,
peripheral blood stem cells (PBSCs) have now virtually
replaced bone marrow as the primary source of stem cells for
autologous transplantation (Gratwohl et al, 1996, 1998).
Monitoring the rise in circulating CD34 PBSCs using ¯ow
cytometry enables the optimum time point to harvest such
cells by leucapheresis to be determined. However, a variety of
different ¯ow cytometric approaches have been developed
(Bender et al, 1992; Sutherland et al, 1996; Gratama et al,
1997; Verwer & Ward, 1997; Keeney et al, 1998). This has
consequently resulted in a lack of standardization and
unacceptably high interlaboratory variation, with respect to
reagents, gating strategies and techniques used to derive
absolute CD34 PBSC values (Brecher et al, 1996; Chang &
Ma, 1996; Johnsen & Knudsen, 1996; Lowdell & Bainbridge,
1996; Lumley et al, 1996; Chin-Yee et al, 1997; Gratama
et al, 1997; Dzik et al, 2000) Thus, the minimum threshold
dose of PBSCs required to obtain adequate engraftment can
be affected by this lack of ¯ow cytometric standardization
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and also by other factors, such as: (i) bone marrow function
at the time of stem cell collection (i.e. effects of prior
cytoreductive therapy); (ii) the preparative regimen before
reinfusion (i.e. myeloablative vs. non-myeloablative); and (iii)
the composition of the stem cell graft, i.e. the balance of
subpopulations of CD34 haematopoietic stem cell (HSC)
(Perey et al, 1998).
The CD34 Task Force of the European Working Group of
Clinical Cell Analysis (EWGCCA) wishes to address, in a
multicentre study, the effect of absolute number of CD34
cells infused as well as subset composition of the stem cell
graft on short- and long-term engraftment. Therefore, it is
essential that the ¯ow cytometric determination of CD34
stem cells be standardized. Thus, the 24 centres enrolled into
this study agreed to do so using a single-platform ¯ow cyto-
metric technique and standardized reagents to assess absolute
CD34 cell counts and CD34 subsets (Gratama et al, 1999).
Importantly, the use of single-platform approaches have
recently been shown to result in interlaboratory variations of
< 20% when compared with the so-called `dual-platform'
approach (Barnett et al, 1999). Therefore, we initiated an
educational external quality assessment (EQA) programme
for absolute CD34 cell counting and CD34 subset
enumeration in order to minimize the variation within and
between laboratories. This educational programme differs
from previous approaches (Johnsen et al, 1999) in that
`on-site' laboratory standardization was undertaken rather
than a workshop on a single site and that stabilized blood
products, validated for use in EQA programmes for CD34
PBSC enumeration (Barnett et al, 1998), were used. In this
way, the in¯uence of specimen deterioration, occurring with
fresh or cryopreserved material on the EQA results was
eliminated (Barnett et al, 1998).
The ®rst part of this programme set out to standardize
absolute CD34 cell counts at a level representative for
apheresis products (i.e. 150±200 CD34 cells/mm3). The
goals were: (i) to reduce the interlaboratory coef®cient of
variation (CV) to < 10% and (ii) to obtain, in > 75% of the
participants, an intralaboratory CV < 5%, but not exceeding
10% for any participant. Here, we report the results of
three send-outs and show, in comparison to the results of
simultaneous send-outs by the UK National External
Quality Assessment Scheme (NEQAS) for CD34 Stem
Cell Quanti®cation Scheme using the same test samples, the
bene®cial effects of such an educational programme on the
interlaboratory variation in CD34 stem cell enumeration.
METHODS
Study design. This study was designed in order to stan-
dardize, monitor and improve the assessment of CD34
absolute counts in a group of 24 different laboratories
located in seven European countries. For that purpose,
several items were considered in advance: (i) sample to be
used; (ii) reagents; (iii) sample preparation protocols; (iv) data
acquisition, analysis and reporting; and (v) monitoring of
potential problems occurring during the trial.
The specimen used in each instance was a well-charac-
terized stabilized sample, similar in composition to mobilized
peripheral blood (PB) (Barnett et al, 1998). To standardize
sample staining/labelling, reagents from the same source
and clones were used in each trial in all participating centres.
Moreover, any technical issues that may have an impact
on the quality of the results obtained, i.e. type of lysing
solution to be used, single- vs. dual-platform assay, were
resolved before the trials (Menendez et al, 1998; Barnett et al,
1999). The de®nition of the single-platform and dual-
platform approaches have been described elsewhere (Barnett
et al, 1999). Brie¯y, a single-platform approach facilitates the
absolute count determination of leucocyte subsets directly
from the ¯ow cytometer by either adding a known number of
microbeads to the sample or by calculating the number of
cells in a known volume. In the dual-platform approach, the
absolute leucocyte subset count is a product of the absolute
total leucocyte count derived from an haematology analyser
and the percentage of the leucocyte subset derived immuno-
logically from the ¯ow cytometer. Furthermore, to ensure
standardized sample preparation procedures, a written proto-
col was distributed to all participants and, before commence-
ment, a `wet workshop' was conducted for all technical and
clinical staff responsible for the study in each laboratory.
A common reporting form was distributed with samples
to each participating centre, with all data generated being
analysed centrally. To resolve any technical problems that
occurred during the trial, a co-ordinating centre existed in
each country that was responsible for direct contact with
each laboratory within their territory.
Specimen collection and distribution. For each trial, 200 ml
of peripheral blood was obtained, after informed consent,
from a normal individual and was spiked with a known
number of CD34 cells, typically to a ®nal concentration of
between 150 and 210 cells/ml. An acute myeloid leukaemia
that presented with a 100% CD34 blast cell count was used
as the source of CD34 cells, the blasts having charac-
teristics identical to the normal human PB HSC regarding
their light scatter characteristics [forward light scatter
(FSC)low to intermediate, side light scatter (SSC)(low], and the
expression of the CD34 and CD45 antigens (CD34 and
CD45dim). The material was stabilized using a procedure
described in detail previously (Barnett & Granger, 1998).
Longitudinal studies have shown that ¯ow cytometric pro®les
and the expression of CD34 and CD45 are stable for over
600 d by this protocol (Barnett et al, 1996, 1998).
Three trials involving a total of 24 laboratories in seven
European countries (four laboratories in The Netherlands,
two in Germany, one in France, one in Switzerland, four in
the UK, two in Spain and 10 in Italy) were conducted over a
6-month period. Of the 24 participating laboratories, 21
used a Becton±Dickinson ¯ow cytometer, two used a Coulter
¯ow cytometer and one used an Ortho CytoronAbsolute.
Before commencement of the study, each centre was ran-
domly assigned a laboratory code number (1±24) that
maintained between-site con®dentiality, this code number
was retained throughout. Only each national co-ordinator
and the relevant site knew the code numbers assigned. One
laboratory (site 16) stopped routine CD34 cell enumeration
after the second trial and did not participate further in the
study. Another site (site 24) joined the project from trial 2
onwards. The ®rst trial determined the absolute CD34 stem
cell count using Flow-Count beads, and Flow-Count and
TruCount beads were evaluated in parallel in trials 2 and 3.
Each participant was requested to perform six replicate
analyses using Flow-Count on three occasions for trial 1 and
three replicate analyses for each type of counting beads on
three occasions for trials 2 and 3. Before commencement of
the study, it was agreed that after each trial the participating
laboratories were debriefed and advice given where appro-
priate. It was also agreed that to consider the planned clinical
multicentre trial feasible: (i) > 75% of laboratories should
have attained an intralaboratory CV < 5% but not exceeding
10% for any participant and (ii) an interlaboratory variation
of # 10% should be reached at the level of 150±200 CD34
cells/ml.
For each trial, the participating sites were provided with
1´5 ml of stabilized peripheral blood and suf®cient reagents
to perform single-platform CD34 stem cell enumeration,
and an English language standard operating procedure (see
below). The reagents issued for trial 1 were CD45 FITC (clone
2D1), CD34 PE (clone 8G12) both from Becton-Dickinson
BioSciences (San Jose, USA), Ortho-Mune lysing reagent
(Ortho Diagnostic Systems, Raritan, New Jersey, USA) and
Flow-Count beads (Coulter-Immunotech, Miami, Florida,
USA). For trials 2 and 3, the same set of reagents were issued
along with TruCount tubes (Becton-Dickinson BioSciences,
San Jose, USA).
The samples used for trials 2 and 3 were simultaneously
issued to 110 laboratories enrolled in the UK NEQAS for
CD34 Stem Cell Quanti®cation, of which 98 and 97 par-
ticipants, respectively, returned results for the trials. This
group of laboratories used either non-standardized tech-
niques (86 and 80 laboratories for trials 2 and 3 respectively)
or commercial kits ± Stem-Kit (Coulter-Immunotech) or
ProCount (Becton-Dickinson) (12 laboratories in trial 2 and
17 laboratories in trial 3).
Standard protocol for CD34 cell enumeration. Sample
preparation using Flow-Count beads, ¯ow cytometric data
acquisition and data analyses were performed as described
by Gratama et al (1999). Brie¯y, 10 ml of mAb (dilution) were
pipetted in duplicate to the bottom of 12 ´ 75 mm polystyrene
tubes, followed by 100 ml of sample. After a 15-min incu-
bation of the samples with mAb mixture at room tempera-
ture (RT), 2 ml of each lysing reagent was added to the
respective tubes for a further 10 min incubation at RT. To
each tube, 100 ml of the Flow-Count bead suspension was
added immediately before data acquisition. All samples were
kept on melting ice until data acquisition, which was
performed within 1 h after completion of sample preparation.
Samples and counting beads were aliquoted using an elec-
tronic pipette using reverse pipetting (Barnett et al, 1999).
For data acquisition of samples evaluated using Flow-Count,
the forward light scatter (FSC) threshold was set at a suf®ci-
ently low level so as not to exclude the counting beads.
Samples issued for trials 2 and 3 were also analysed using
TruCount tubes. These are 12 ´ 75 mm polystyrene tubes
containing a prede®ned number of TruCount beads. The
same staining procedure was adopted as described above
except that the Flow-Count beads were omitted. During
acquisition, the very low FSC signals of TruCount beads
precluded the use of the FSC threshold as described for the
Flow-Count beads and, thus, FL1 was used as the threshold
to exclude debris, i.e. CD45ÿ events (Fig 1A and B). Suf®cient
events were collected so as to contain at least 100 CD34
cells (FSClow to intermediate,SSClow,CD34,CD45dim).
An overview of the sequential Boolean gating strategy
used for list mode data analysis for Flow-Count beads has
been published in Gratama et al (1999) and is shown for
TruCount beads in Fig 1. In the ®rst step, CD45neg events (i.e.
most debris, platelets and unlysed erythrocytes) were
excluded (R1 in Fig 1A). The CD45dim border of the CD45
window (R1) was veri®ed on a CD45 vs. CD34 plot of
ungated data (Fig 1E) to prevent exclusion of any CD34
events at this stage. The selected leucocytes (R1) were then
displayed in a CD34 vs. SSC dot plot (Fig 1B). The CD34
events were selected (R2) and displayed on a CD45 vs. SSC
dot plot (Fig 1C). The cluster of SSClow,CD45dim events was
selected (R3) and displayed on a FSC vs. SSC dot plot (Fig 1D).
Any events that did not meet the FSC,SSC criteria of viable
leucocytes were excluded by setting a fourth window (R4), of
which the FSClow left border was veri®ed using the FSC and
SSC signals of lymphocytes (selected by R5 and displayed in
Fig 1F). `True' CD34 HPC must ful®l the criteria of R1, R2,
R3 and R4. The counting beads were analysed by drawing a
small rectangular gate (R6) to include the brightest events
that fall in the highest FL1 and FL2 ¯uorescence channels
(Fig 1E). The events from R6 were displayed in a time vs. FSC
dot plot (Fig 1G) in order to exclude any `non-bead' events
(i.e. falling outside R7). The absolute number of CD34 cells
(per ml) was calculated by multiplying the number of `true'
CD34 events by bead concentration and dilution factor,
followed by division by the number of beads counted (i.e.
number of events ful®lling R6 and R7).
Statistical analyses. Statistical analyses were performed
using SAS (Statistical Analysis Systems, Cary, NC, USA) and
Stata (Stata Corporation, College Station, TX, USA) software.
For each trial and type of counting bead, the median result
and CV of the number of CD34 cells for each laboratory
were calculated. The median result of each laboratory was
used to calculate the group median, 10th and 90th per-
centiles (indicated in each panel of Fig 2), as well as the
interlaboratory CV for each trial and type of counting bead.
A laboratory exceeding the 10th and 90th percentile was
considered as an outlier.
RESULTS
Intralaboratory variation
Figure 2 shows the results of the CD34 stem cell enumer-
ations performed six times (trial 1) or in triplicate (trials
2 and 3) strati®ed by trial and type of counting bead.
Histograms of the intralaboratory CVs, plotted by trial and
type of counting bead, are shown in Fig 3.
Flow-Count beads. For trial 1, the median intralaboratory
CV was 6´1%. Nine (39%) of the 23 participants had an
intralaboratory CV < 5%. Laboratories 4 and 8 had the
highest intralaboratory CVs of 10´5% and 14´1% respec-
tively. For trial 2, the median intralaboratory CV improved to
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2´7% with 16 (70%) of the 23 participants having an
intralaboratory CV < 5%. Two laboratories, 9 and 23, were
outliers, having intralaboratory CVs of 13´4% and 25´1%
respectively. Laboratories 4 and 8 had improved their per-
formance with intralaboratory CVs of < 1% in both cases.
For trial 3, the median intralaboratory CV was 3´5%; 15 of
the 23 participants (65%) now attained an intralaboratory
CV < 5%. Laboratory 23 had improved its intralaboratory
CV to 2´6%, whereas laboratory 9 kept underperforming,
with an intralaboratory CV of 15´0%. Interestingly, both
Coulter users achieved intralaboratory CVs of 2´9% and
2´4% respectively.
TruCount beads. The number of laboratories attaining the
target intralaboratory CV of < 5% in trials 2 and 3 was 15
and 19 respectively. For trial 2, the median intralaboratory
CV was 3´8%, with 15 (65%) of the 23 participants having
an intralaboratory CV < 5%. Laboratories 6 and 10
performed relatively poorly with intralaboratory CVs of
10´8% and 15´0% respectively. For trial 3, the median
intralaboratory CV was reduced further to 2´1%, with 19
(83%) of the 23 participants having an intralaboratory CV
< 5%. In this round, laboratory 18 was an outlier, with an
intralaboratory CV of 14´3%, whereas laboratories 6 and 10
had improved their intralaboratory CVs to 4´9% and 1´8%
respectively. Indeed, using TruCount, 13 laboratories showed
a decrease in their intralaboratory CVs between trials 2 and
3, with 11 of these having an intralaboratory CV of between
0´98% and 3´57%.
Fig 1. Analysis of sample 3 prepared with
TruCount beads then acquired and analysed
according to the standard protocol on a Becton
Dickinson FACSCan. See further information in
Materials and methods.
Differences in intralaboratory CVs using Flow-Count and
TruCount beads did not reach statistical signi®cance either
for trial 2 (P0´23) or for trial 3 (P0´06 using the
Wilcoxon test).
Interlaboratory variation
The variation between the laboratories is shown in Fig 4 and
is summarized in Table I.
Flow-Count beads. During trial 1, laboratories 1 and 13 were
clear outliers, with median results > 300 CD34 cells/mm3,
whereas the 90th percentile of the group was 248 CD34
cells/mm3 (Fig 2). The interquartile range (Fig 4) was
61 CD34 cells/mm3 and the interlaboratory CV was 23´3%.
During trial 2, the interquartile range decreased to 35
CD34/mm3 and interlaboratory CV decreased slightly to
18´7%; this time, laboratories 7 and 17 (the latter per-
forming only a single analysis because of instrument
problems) obtained exceedingly high CD34 cell counts.
The interquartile range decreased further to 14 CD34 cells/
mm3 in trial 3. Only moderate outliers were observed
(laboratories 3 and 15), hence the interlaboratory CV fell to
10´8%, i.e. almost at the target level set out at the beginning
of the project.
TruCount beads. The interquartile range in trial 2 was
only 15 CD34 cells/mm3. However, laboratories 7 and 22
signi®cantly contributed with their high outliers to the
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Fig 2. Intra- and interlaboratory variation in
results of assessments of absolute numbers of
CD34 cells. The median values of assessments
carried out six times (trial 1) or in triplicate for
each type of counting bead (trials 2 and 3) are
connected with a line. The horizontal lines
indicate, for each trial and type of counting
bead, the 10th, 50th (median) and 90th
percentiles (for computation, see Materials and
methods).
Table I. Interlaboratory CV of absolute CD34 cell numbers in the
EWGCCA trials and the UK NEQAS send-outs.
EWGCCA UK NEQAS
Trial Flow-Count TruCount Dual platform Single platform
1 23´3 ND
2 18´7 23´4 17´6 17´2
3 10´8 9´5 34´4 17´5
ND, not done.
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Fig 3. Histograms showing the distribution
of intralaboratory CVs per trial and type of
counting bead. The lines at CV5% indicate
the target level set for the multicentre clinical
trial and are shown as a reference.
Fig 4. Variation in absolute numbers of CD34
cells/mm3 between laboratories participating
in the three EWGCCA trials and the two UK
NEQAS CD34 Stem Cell Enumeration Scheme
send-outs. The boxes extend from the 25th
(p25) to the 75th (p75) percentile; the line
in the middle represents the median. The
whiskers extend to the upper and lower
adjacent values, which are de®ned as
1´5 ´ (p75±p25), rolled back to where there
are data. Outliers more extreme than the
adjacent values have been individually plotted.
Numbers 1±3 denote EWGCCA trial numbers.
The UK NEQAS results on the same samples as
used for trials 2 and 3 are shown adjacent to
the corresponding EWGCCA results. Flow,
Flow-Count; Truc, TruCount; Dual, dual-
platform assays; Sing, single platform assays.
interlaboratory CV of 23´4% (Fig 2). The interquartile range
remained at 16 CD34 cells/mm3 in trial 3. This time, only
moderate outliers were seen (Fig 4) by laboratories 11 (low),
18 (high) and, again, 22 (high); as a result, the interlabora-
tory CV fell to 9´5%, i.e. to target level.
Comparison between laboratories participating in EWGCCA
trials and UK NEQAS send-outs
For trials 2 and 3, the same samples were also analysed and
reported by 98 and 97 laboratories participating in the UK
NEQAS for CD34 Stem Cell Quanti®cation programme
respectively. The results of both groups are shown in Fig 4,
with results strati®ed for type of counting bead (i.e. Flow-
Count vs. TruCount), for the EWGCCA participants and for
assay type (i.e. dual platform vs. single platform) for the UK
NEQAS participants.
For trial 2, the UK NEQAS laboratories (using dual
platform or single platform) obtained slightly, but signi®-
cantly, lower absolute CD34 cell counts (median 180 and
181 CD34 cells/mm3 respectively) than the EWGCCA labs
(Flow-Count, 189 CD34 cells/mm3; TruCount, 190 CD34
cells/mm3; P0´03, Kruskal±Wallis test). The smallest
interquartile range was observed for the EWGCCA partici-
pants using TruCount beads (15 CD34 cells/mm3 vs. 35,
36 and 32 CD34 cells/mm3 for EWGCCA participants using
Flow-Count beads and UK NEQAS participants using dual-
and single-platform assays respectively). However, because of
the presence of ®ve outliers in the EWGCCA results compared
with only a single outlier in the UK NEQAS results, the
interlaboratory CVs of the UK NEQAS dual- and single-
platform groups (17´6% and 17´2% respectively) were lower
than those of the EWGCCA groups (18´7% and 23´4%
respectively; (Table I).
For trial 3, the EWGCCA and UK NEQAS participants
obtained similar absolute numbers of CD34 cells. The
medians were: EWGCCA (Flow-Count), 162 CD34 cells/
mm3; EWGCCA (TruCount) 161 CD34 cells/mm3; UK
NEQAS (dual platform), 157 CD34 cells/mm3; and UK
NEQAS (single platform), 162 CD34 cells/mm3. The
smallest interquartile range was observed for EWGCCA
(Flow-Count), 14 CD34 cells/mm3, followed by EWGCCA
(TruCount), 16 CD34 cells/mm3, UK NEQAS (single plat-
form), 18 CD34 cells/mm3, and UK NEQAS (dual platform)
28 CD34 cells/mm3. Because of the large number of
outliers (n8), the UK NEQAS double-platform group had
increased from 17´6% in trial 2 to 34´4% in trial 3, whereas
the CV of the UK NEQAS single-platform group remained at
the same level (17´2% in trial 2 and 17´5% in trial 3). These
CVs were clearly higher than those obtained by the EWGCCA
group (Flow-Count, 10´8%; TruCount, 9´5%).
Problems identi®ed during the course of the study
During the ®rst trial, several problems became apparent,
such as that the templates supplied on disc were not com-
patible with all software used by participants, thus two
laboratories had to de®ne gating criteria that were slightly
different to the remaining participants. This problem was
recti®ed before the next trial. During trial 1, several labora-
tories reported increased doublet, triplet and quadruplet
bead formation with the Flow-Count beads. The cause of this
problem was thought to arise from the aliquoting of Flow-
Count beads by the co-ordinating laboratory from manu-
facturer vials into smaller secondary vials before distribution
among participants. Variation in how these populations were
included within the calculation of PBSCs would therefore be
one of the factors affecting the intra- and interlaboratory
CVs. Therefore, all participants were provided with factory-
sealed Flow-Count vials before commencing trials 2 and 3.
During the course of the study, several sites were identi®ed
as having speci®c problems. The staff performing trial 2 at
laboratory 7 were insuf®ciently pro®cient in English and
made errors using both counting bead systems (Fig 1). After
instructions and trouble-shooting had been provided in their
native language, their performance in trial 3 improved.
Laboratory 17 returned only one result for trial 2 as a con-
sequence of instrumentation failure. Laboratory 9 had results
out of consensus for trials 2 and 3. Further investigation
found the causes to be (i) an increased number of doublet,
triplet and quadruplet beads using Flow-Count for trial 2 and
(ii) the automatic pipette used during trial 3 was dispensing
incorrect volumes as a result of low battery power. When the
batteries were replaced, the problem was recti®ed and the
intra- and interlaboratory CV improved to achieve the target
CVs required. Laboratory 18, with results in trial 3 higher
than the 90th percentile, had problems owing to faulty
TruCount tubes. Their performance improved signi®cantly
when new reagents, tubes and samples were issued.
After trials 2 and 3, several sites received additional train-
ing in order to address problems that had occurred. The
problems identi®ed were either a high intralaboratory CV
and/or outlying results (> 90th or < 10th percentiles). After
training, all but one site showed improved performance
when they tested the same material again, i.e. intralaboratory
CVs were reduced to < 5% and/or the median of the triplicate
results fell within the 10th and 90th percentiles.
DISCUSSION
Using stabilized samples prepared by UK NEQAS for leuco-
cyte immunophenotyping, and having PBSC concentrations
representative of leucapheresis samples (typically > 150 cells/
ml), three separate EWGCCA CD34 task force (TF) trials were
conducted. It is important to stress that the stabilized whole
blood material used in this study had minimal, if any, matrix
effects. Such an effect is de®ned as having interassay
properties similar to those of a patient specimen and does
not contain, within the specimen, a component that will
in¯uence the parameter(s) to be analysed. Material stabilized
in a manner previously described (Barnett & Granger, 1998)
has been previously demonstrated to satisfy these criteria
and to be compatible with all ¯ow cytometers (Barnett et al,
1996, 1998, 1999).
It is well recognized that single-platform ¯ow cytometric
analysis of cellular subsets results in lower interlaboratory
variation and is the preferred approach (Margolick et al,
1998; Barnett et al, 1999; Reimann et al, 2000; Schnizlein-
Bick et al, 2000). Thus, using this state-of-the-art approach,
the EWGCCA CD34 TF have evaluated two single-platform
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approaches using beads as reference values, one using Flow-
Count beads and the other TruCount beads (Keeney et al,
1998; Gratama et al, 1999). Both of the protocols utilized
the previously described International Society for Haema-
totherapy and Graft Engineering (ISHAGE) gating strategy,
but have been modi®ed to enable single-platform analysis.
After each trial, participants were debriefed and assistance
was provided where required. This study had a primary
objective of reducing interlaboratory variation to < 10%
while achieving an intralaboratory CV of < 5% in at least
75% of participating centres, but not exceeding 10% in all
centres, using a standardized single-platform ¯ow cytometric
technique. The EWGCCA CD34 TF arbitrarily set these
goals to enable generation of reliable data in a multicentre
clinical study aimed at determining the precise numbers of
CD34 HSC (and subsets) required that obtained adequate
engraftment.
The high intralaboratory CV observed in the ®rst trial
using Flow-Count and the fact that the majority of labora-
tories failed to achieve an intralaboratory CV of < 5% could
be the result of two factors: (i) unfamiliarity of the reverse
pipetting technique, a prerequisite for single-platform ¯ow
cytometric analysis (Connelly et al, 1995; Mercolino et al,
1995; Strauss et al, 1996) and (ii) problems encountered
when the Flow-Count beads were subaliquoted centrally.
However, when trial 2 was conducted, the majority of
laboratories attained a CV of 5% (or less), suggesting that
laboratories had become familiar with the technique. This
hypothesis was supported by the fact that for trial 3 using
Flow-Count the improvement was sustained, with all except
three laboratories attaining an intralaboratory CV of < 10%
and the interlaboratory CV was very close to the target CV of
10%. However, by trial 3 when using TruCount tubes, all
laboratories, except one, had an intralaboratory CV of < 10%
and the interlaboratory CV reached the target value of < 10%.
Trials 2 and 3 were also performed in parallel with the UK
NEQAS for CD34 Stem Enumeration scheme. The EWGCCA
sites were compared with the UK NEQAS sites using the
single-platform approaches Stem-Kit and ProCount. The trial
2 median value for the UK NEQAS cohort was slightly, but
signi®cantly, lower than the median value obtained by the
EWGCCA cohort, but this was not reproduced in trial 3. No
obvious cause for this difference was determined. It has
previously been demonstrated by the UK NEQAS scheme that
use of single-platform methods signi®cantly reduces inter-
laboratory variance compared with the use of dual-platform
methods (Barnett et al, 1999). However, it should be noted
that the UK NEQAS cohort did not use standardized
methodology. Furthermore, Bergeron et al (1998) demon-
strated that when using a standardized approach for CD4
T-lymphocyte enumeration a signi®cant improvement in
interlaboratory variance is observed. This current EWGCCA
study has extended these ®ndings to CD34 stem cell
enumeration and also supports the UK NEQAS observations
that a single-platform ¯ow cytometric approach does result
in reduced interlaboratory variation. However, this EWGCCA
study has extended these ®ndings and has shown that, with
appropriate training, the use of TruCount tubes and a
standardized single-platform approach, interlaboratory CVs
lower than those previously reported by UK NEQAS can be
obtained and the target CV de®ned before study commence-
ment can be attained.
Thus, in conclusion, we have demonstrated that, using a
standardized `state-of-the art' single-platform CD34 stem
cell ¯ow cytometric method intralaboratory, CVs can be
reduced to < 5%. Continuous education and targeted train-
ing of individual laboratories form a critical component of
this improvement. Furthermore, using such an approach, i.e.
EQA with stable whole-blood material free from any matrix
effect, interlaboratory variation can be reduced to below
10% in the majority of laboratories. This is a prerequisite to
achieving meaningful multicentre clinical study data.
Further trials are now planned to monitor these parameters
and also to undertake the monitoring of CD34 subsets.
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APPENDIX
The following centres participated in this study: France, E.
Wunder and H. Sovalat (HoÃpital Hasenrain, Mulhouse);
Germany, M. BornhaÈuser and U. OelschlaÈgel (UniversitaÈtsk-
linikum, Dresden), G. Rothe and S. Barlage (Klinikum der
UniversitaÈt Regensburg, Regensburg); Italy, R. Lemoli and
D. Rondelli (Istituto Di Ematologia `Seragnoli', Bologna),
F. Lanza and S. Moretti (Ospedale S. Anna, Ferrara),
R. Saccardi and R. Caporale (Azienda Ospedaliera Careggi,
Firenze), R. Cairoli and B. Brando (Ospedale Niguarda-
Ca' Granda, Milan), M. Bregni and S. Rossini (H. San
Raffaele, Milan), M. Danova and G. Comolli (Oncologia
Medica e Biotecnologie, IRCCS Policlinico S. Matteo, Pavia),
G. Pagnucco and L. Vanelli (Ematologia, IRCCS Policlinico
S. Matteo, Pavia), A. Tabilio and D. Alfonsi (Policlinico
Monteluce, Perugia), F. Benedetti and D. De Sabata (Ospedale
Policlinico, Verona); The Netherlands, G. J. Schuurhuis and
G. Westra (Academisch Ziekenhuis Vrije Universiteit),
F. Preijers and M. Leenders (Academisch Ziekenhuis St.
Radboud, Nijmegen), M. B. van `t Veer and J. Kraan
(Academisch Ziekenhuis-Daniel den Hoed Kliniek, Rotter-
dam), E. Braakman and P. van Geel (Academisch Ziekenhuis-
Erasmus Universiteit, Rotterdam); Spain, J. J. Lahuerta and
M. A. Montalban Pallares (Hospital Universitario 12 de
Octubre, Madrid), A. Orfao and P. MeneÂndez (Hospital
Universitario de Salamanca, Salamanca); Switzerland,
A. Huber and L. Stempora (Kantonsspital Aarau, Aarau);
UK, S. Maclennan and A. Lubenko (Leeds Blood Centre,
Leeds), S. Richards and A. Rawstron (Leeds General In®rm-
ary, Leeds), N. H. Russell and C. Stainer (Nottingham City
Hospital, Nottingham), J. T. Reilly and I. Storie (Royal
Hallamshire Hospital, Shef®eld).
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